| March 3 |
Pro-Pharmaceuticals Davanat Extends Median Survival 6.7 Months for
End-Stage Colorectal Cancer Patients After All Other Treatments
Failed |
| March 3 |
Renovo Announces Results of Latest Phase 2 Studies of Juvista
(Human Recombinant TGFbeta3) |
| March 3 |
Publication in Clinical Cancer Research Confirms Ability of
Peregrine's Bavituximab to Target Tumor Blood Vessels with
Excellent Specificity |
| March 3 |
GTx Announces Additional Top Line Phase III Data Demonstrating
Toremifene Citrate 80 mg Reduced Hot Flashes in Men with Prostate
Cancer on Androgen Deprivation Therapy |
| March 3 |
Alexza's AZ-104 (Staccato Loxapine) Phase 2a Trial Meets Primary
Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache |
| March 3 |
HUYA Bioscience Int'l Announces Clinical Trial Milestones in China
for Promising New Anti-Arrhythmic Compound; Data Supports Desirable
Safety Profile |
| March 3 |
LifeCycle Pharma Announces Positive Top-line Results of Phase II
Clinical Trial of LCP-Tacro for the Prevention of Organ Rejection
after Kidney Transplantation |
| March 3 |
Array BioPharma Announces Positive Phase 2 Top-Line Results in
Inflammatory Pain Clinical Trial |
| March 3 |
PhytoMedical's Latest Anti-Cancer Compounds Kill Human Colon Cancer
Cells |
| March 3 |
Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of
Antigen Presenting Cell Activation |
| March 4 |
Inovio Biomedical to Present New Data from Melanoma Immunotherapy
Clinical Trial at DNA Vaccines Forum 2008 |
| March 4 |
Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595
at the 39th Annual Meeting on Women's Cancer |
| March 4 |
Sirtris Pharmaceuticals' SRT501 Slows Retinal Ganglion Cell Loss
During Optic Neuritis in a Preclinical Model of Multiple Sclerosis |
| March 4 |
Advaxis Scientists Publish Research of Listeria Monocytogenes-Based
Vaccine for Prostate Cancer in Latest Edition of Cancer Immunology
& Immunotherapy |
| March 4 |
Lifetime Probability of Needing a Stem Cell Transplant is Much
Higher Than Previously Reported, Data Shows |
| March 4 |
International symposium reports on the use of antivirals in
patients with H5N1 |
| March 4 |
Panacos Announces Discovery of Bevirimat Patient Response
Predictors |
| March 4 |
UCB: Early Data on Cimzia from the WELCOME Study Show Efficacy in
Infliximab-Refractory Crohn's Disease Patients |
| March 5 |
CHOP-Zevalin Investigational Regimen Produces 95% Complete
Remission and 75% Estimated Two Year Progression-Free Survival in
Elderly Patients with Diffuse Large B-cell Lymphoma |
| March 5 |
Microbia and Forest Laboratories Announce Preliminary Results of
Linaclotide Phase 2b Studies |
| March 5 |
Synvista Therapeutics Highlights Newly Published Data Demonstrating
the Value of Haptoglobin Genotype Testing In People with Diabetes |
| March 6 |
PharmAthene Completes Pharmacokinetic Studies of Protexia; Program
on Target for IND Filing in 2008 |
| March 6 |
Leukemia Therapy With Imatinib During Pregnancy May Cause Infant
Abnormalities |
| March 6 |
High Levels of Estrogen Associated with Breast Cancer Recurrence |
| March 6 |
ProMetic reports continued positive data in PBI-1402 phase II trial
in chemotherapy-induced anemia |
| March 7 |
Alcon Presents Clinical Trial Data on Anecortave Acetate for
Glaucoma |
| March 7 |
Juvista Phase II Trial Results in Scar Revision and Breast
Augmentation Surgery |
| March 7 |
Repros' Proellex Safety Data Presented At The 13th World Congress
of Gynecological Endocrinology |
| March 7 |
THE LANCET Publishes Phase IIa Study Results with Cytos
Biotechnology’s Hypertension Vaccine CYT006-AngQb |
| March 7 |
SPMSD release: Gardasil |
| March 7 |
Experts Available to Discuss Study Showing Link Between High Levels
of Estrogen and Breast Cancer Recurrence |
| March 10 |
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical
Trial Fails to Meet Primary Efficacy Endpoint |
| March 10 |
Palatin Technologies, Inc. Reports Positive Results of a Phase I
Clinical Study With PL-3994 for the Treatment of Congestive Heart
Failure |
| March 10 |
Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595
Single-Agent Activity in Platinum-Resistant Ovarian Cancer |
| March 10 |
Sirtris Pharmaceuticals Collaborator Presents Neuroprotective Data
for Oral Drug Candidate SRT501 at North American
Neuro-Ophthalmology Society Meeting |
| March 10 |
Genzyme Announces Presentation of New Positive Data on Carticel |
| March 10 |
GSK Cervical Cancer Candidate Vaccine Cervarix Demonstrates
Long-Term Protection for More Than Six Years |
| March 10 |
Anavex 7-1037 Reduces Rate of Cancer Tumor Growth 69% in
Preclinical Studies, Compared to Currently Marketed Drug
Dacarbazine Showing no Measurable Activity |
| March 10 |
Complete ANX-530 Safety Data to be Published in the 2008
Proceedings of the American Society of Clinical Oncology |
| March 10 |
Independent Physician Surveys Show if Approved, MF101 Could Become
First-Line Treatment for Menopause Symptoms |
| March 10 |
Clinical Data on Lenocta, a Protein Tyrosine Phosphatase Inhibitor
in Development at VioQuest Pharmaceuticals, Accepted for Oral
Presentation at ASCO |
| March 10 |
Potential Brain Cancer Drug for Children May Damage Bones |
| March 10 |
Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter
(DAT) Blocker Preclinical Data at the American Society for
Experimental NeuroTherapeutics (ASENT) Conference |
| March 11 |
I-Flow Leads Infection Prevention Trend by Using Silver with
Antimicrobial Properties in Medical Devices |
| March 11 |
Genitope Corporation to Suspend Development of MyVax Personalized
Immunotherapy |
| March 11 |
Femara helps protect against return of breast cancer even when
treatment starts several years after completing tamoxifen therapy |
| March 11 |
Halozyme Therapeutics Presents Favorable New Safety and
Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New
Manufacturing Process at European Federation for Pharmaceutical
Sciences |
| March 11 |
Inovio Biomedical's Electroporation Delivery Technology
Demonstrates Safety and Positive Clinical Responses with Melanoma
DNA Immunotherapy |
| March 11 |
Peregrine Pharmaceuticals Announces Positive Data From Cotara Brain
Cancer Trials |
| March 11 |
Oculus Innovative Sciences to Announce Additional Phase II Data and
Data from Two Recent International Studies at DFCon 08 |
| March 11 |
Nymox Releases Further Results from Latest U.S. Study of NX-1207
for Benign Prostatic Hyperplasia |
| March 11 |
Oxogeme Reports Positive Primate Ocular Tolerance and Penetration
Data with Topical Formulation of Zybrestat for Ophthalmology |
| March 11 |
Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at
ASCO |
| March 11 |
Nymox Releases Further Results from Latest U.S. Study of NX-1207
for Benign Prostatic Hyperplasia |
| March 12 |
Wyeth and Progenics Provide Update on Phase 3 Clinical Trial of
Intravenous Methylnaltrexone for Postoperative Ileus |
| March 12 |
Avexa Reports Superior Results in ATC Phase IIb Clinical Trial
Update |
| March 12 |
Urigen Announces Positive Phase II Clinical Trial Results with
URG101 |
| March 12 |
XenoPort Announces Positive Results of a Phase 1 Clinical Trial of
XP21279 |
| March 12 |
Unigene Successfully Completes Phase I/II Clinical Study for Oral
Calcitonin |
| March 12 |
JAMA Article Provides False Support for CDC's Do-Nothing Position
on MRSA |
| March 12 |
CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2
Results in Psoriasis |
| March 12 |
OctoPlus Announces Publication of Phase I Locteron Results in the
Journal of Interferon and Cytokine Research |
| March 13 |
Publication of Clinical Results Underscores Velcade (Bortezomib)
For Injection Based Therapy As a Standard of Care In Newly
Diagnosed Multiple Myeloma Patients |
| March 13 |
Amicus Therapeutics Presents Positive Data from Phase 2 Clinical
Trial of Plicera for Gaucher Disease |
| March 13 |
Cambria Biosciences' Chemical Genetics Platform is Featured in
Nature Article Describing a New Pharmaceutical Mode of Action |
| March 13 |
MacroChem Announces Presentation of Pexiganan Phase 3 Study Results
for Topical Treatment of Diabetic Foot Infection |
| March 13 |
Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic
Lateral Sclerosis |
| March 13 |
Researchers Find Cause of Severe Allergic Reaction to Cancer Drug |
| March 13 |
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response
Study and Phase 1 Studies of AT2220 |
| March 13 |
Oncolytics Biotech Inc. Collaborators to Present Reovirus Research
at AACR Annual Meeting |
| March 14 |
Inspire Announces Poster Presentations at 2008 American Academy of
Allergy, Asthma & Immunology (AAAAI) Annual Meeting |
| March 14 |
Oculus Innovative Sciences Announces Additional Phase II Data for
Microcyn Technology in Mildly Infected Diabetic Foot Ulcers |
| March 14 |
The Lancet Publishes Results From World's First Clinical Trial of a
Fully Bioabsorbable Drug Eluting Coronary Stent |
| March 14 |
Greer Reports Favorable Results of Phase IIb Clinical Trial of
Short Ragweed Sublingual-Oral Immunotherapy at American Academy of
Allergy Asthma and Immunology Annual Meeting |
| March 14 |
Modified Virus Vaccine Shows Promise in Mouse Model of Breast
Cancer |
| March 17 |
Akesis Pharmaceuticals Provides Preliminary Data from Phase IIa
Trial of AKP-020 for Type 2 Diabetes |
| March 17 |
Sepracor Presents Safety Data on Omnaris AQ and Omnaris HFA Nasal
Sprays at American Academy of Allergy Asthma and Immunology (AAAAI) |
| March 17 |
Baxter Presents Latest Clinical Trial Results of Gammagard Liquid
Administered Subcutaneously |
| March 17 |
Medarex Announces Presentations at Annual Meeting of the American
Association for Cancer Research |
| March 17 |
Medivation's Dimebon Stabilizes Behavioral Symptoms in Alzheimer's
Disease Patients, Resulting in Reduced Caregiver Distress |
| March 17 |
Cardiome Announces Positive Interim Phase 2b Results for Oral
Vernakalant and Engages Merrill Lynch as Strategic Advisor |
| March 17 |
Valeant Pharmaceuticals Reports Encouraging Phase IIb Results at
Treatment Week 12 for Taribavirin |
| March 17 |
New Data Show Advair Reduces Asthma-Related Hospitalization and
Emergency Department Visits |
| March 17 |
Fludarabine, Mitoxantrone and Zevalin Produces 96% Complete
Remission Rate in First-Line Treatment of Patients with Follicular
Non-Hodgkin's Lymphoma |
| March 17 |
New Trial Presented at AAAAI Reports that the Growth of Children
2-5 Years Old with Year-Round Allergic Rhinitis Continued According
to Normal Age-Adjusted Distribution Over a 6-Month Treatment with
Nasacort AQ |
| March 17 |
Hepatitis C Virus DNA Vaccine Shows Safety When Delivered by Inovio
Biomedical's Electroporation Delivery System in Phase I/II Clinical
Study at Karolinska University Hospital |
| March 17 |
GSK Data Suggests Efficacy of Advair and Serevent is Not Impacted
by Genetic Profile |
| March 17 |
Greer's Sublingual-Oral Immunotherapy Clinical Trials Supporting
the Safety of Home-Administered Treatment Published in the Annals
of Allergy, Asthma and Immunology |
| March 17 |
New Localized Cancer Treatment for Advanced Retinoblastoma Saves
Children From Having Eyes Removed, Restores Vision in Some Cases |
| March 17 |
Study Shows Privigen 10% Liquid Immunoglobulin Preparation for
Intravenous Use, Is an Effective Replacement Therapy in Patients
with Primary Immune Deficiencies |
| March 17 |
NanoBio Corporation Successfully Completes Phase 2b Study in Herpes
Labialis |
| March 17 |
Study Analyzed Long-Term Symbicort Use in Children With Persistent
Asthma |
| March 17 |
Oculus Innovative Sciences Announces Positive Results From Three
Abstracts Evaluating the Use of Microcyn Technology in Diabetic
Foot Ulcers |
| March 17 |
Oncolytics Biotech Inc. Announces Publication of Research on Immune
Response to Reolysin During a Phase I Clinical Trial |
| March 17 |
Scientists Identify New Leads for Treating Parasitic Worm Disease |
| March 17 |
MediGene Achieves Excellent Efficacy Data of EndoTAG-1 in Clinical
Phase II Trial in Pancreatic Carcinoma |
| March 17 |
Nuvelo Announces Phase 2 Sonoma-3 Trial Did Not Meet Target Product
Profile and Discontinues Alfimeprase Development |
| March 18 |
Hollis-Eden Pharmaceuticals Reports Positive Preliminary Data from
Ongoing Phase I/II Clinical Trial with Triolex in Obese Insulin
Resistant Subjects |
| March 18 |
Micromet Announces Presentation of Five Posters Related to Its
Proprietary BiTE Antibody Platform at Annual Meeting of American
Association for Cancer Research |
| March 18 |
VioQuest Pharmaceuticals Announces Presentations at Annual Meeting
of the American Association for Cancer Research |
| March 18 |
NPS Reports Successful Gattex Extension Study |
| March 18 |
Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV
Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma
Viral Load |
| March 18 |
iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading
Drug Delivery Journal |
| March 18 |
CeraShield Coated Endotracheal Tubes Provide up to 21 Days of
Protection against Bacterial Colonization in Preclinical Testing |
| March 18 |
NovaBay Pharmaceuticals (NBY) Publishes on the Design of New Class
of Antimicrobial Compounds It Named Aganocides |
| March 18 |
BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce
Results from Phase III Clinical Trial of Tavocept |
| March 18 |
Study Compares Bronchodilatory Effects of Symbicort and Advair in
Adults With Asthma |
| March 18 |
C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and
Facial Attacks in Patients with Hereditary Angioedema, According to
Pivotal Study |
| March 18 |
Lipid Sciences' HDL Mimetic Peptide Demonstrates Significant
Anti-Atherosclerosis Effect in a Key Animal Model |
| March 18 |
Data Presented at International Psoriasis Meeting Support Potential
New Role for Biologic Treatment Etanercept in Management of
Childhood Psoriasis |
| March 18 |
Leading Rheumatologists Agree Clinical Remission a Key Goal in
Rheumatoid Arthritis |
| March 18 |
960-Patient Study Demonstrates Zero Blood Stream Infection In
Patients Treated With Angiotech's Novel 5-FU Central Venous
Catheter |
| March 18 |
Lev Presents Results of Phase III Study Supporting Safety and
Efficacy of Cinryze (C1 inhibitor) as Prophylactic Therapy for HAE |
| March 18 |
Orexo's Product NLA Nasal Spray Shows Excellent Local Tolerability
in Patients with Rhinitis |
| March 18 |
Peptimmune Completes Phase I Study with a Novel Peptide Copolymer
for the Treatment of Multiple Sclerosis |
| March 19 |
Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial
Results First to Show Prevention by Early Treatment |
| March 19 |
Poniard Pharmaceuticals Announces Clinical Data From Picoplatin
Oral Phase 1 to Be Presented at the American Association of Cancer
Research Annual Meeting |
| March 19 |
Recent Data Study Suggests Cortisol Could Help Alleviate Suffering
for Those With Chronic Fatigue Syndrome and Fibromyalgia |
| March 19 |
X-ray Images from Liver Phase I Trial Presented at Society for
Interventional Radiology 33rd Annual Scientific Meeting |
| March 20 |
EPIX Pharmaceuticals Announces Discontinuation of PRX-00023
Clinical Development Program |
| March 20 |
Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine
Achieves Protective Levels |
| March 20 |
Adherex to Present ADH-1 Phase I/II Melanoma Trial Data at the 2008
Annual Meeting of the American Society Of Clinical Oncology (ASCO) |
| March 20 |
ZIOPHARM Presents Promising Early Data from Phase Ib Study of
Indibulin at 6th International Symposium on Targeted Anticancer
Therapies |
| March 20 |
RXi Pharmaceuticals to Present Data on the Cellular Mechanism of
RNAi Interference at Keystone Symposia's RNAi, MicroRNA, and
Non-Coding RNA Meeting |
| March 20 |
NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical
Trial in Onychomycosis |
| March 21 |
Antigenics to Present Phase 3 Oncophage (vitespen) Data in Kidney
Cancer at European Association of Urology Annual Congress |
| March 21 |
Molecular Science Could Further Improve Leukemia Survival, Say St.
Jude Researchers |
| March 21 |
International Actemra Rheumatoid Arthritis Study Highlighted in The
Lancet |
| March 21 |
Perioperative Eloxatin-Based Regimen Significantly Reduced the Risk
of Relapse Versus Surgery Alone in Eligible Colorectal Cancer
Patients with Initially Resectable Liver Metastases |
| March 21 |
Novel drug Actemra significantly improves the debilitating symptoms
of Rheumatoid Arthritis in patients who have an inadequate response
to standard therapy |
| March 24 |
MAP Pharmaceuticals Reports Positive Results From Comparative
Pharmacokinetic Trial for its Pediatric Asthma Product Candidate |
| March 24 |
Spectrum Pharmaceuticals Presents Data on SPI-1620, a Novel Adjunct
to Cancer Therapy, at the 6th International Symposium on Targeted
Anticancer Therapies |
| March 24 |
Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study
Demonstrating Zinc Finger Technology for Rapid Generation of
'Knock-Out' Cell Lines |
| March 24 |
Baraclude (entecavir) Data Continue to Demonstrate Low Incidence of
Resistance Through Five Years of Treatment in Nucleoside-naive
Chronic Hepatitis B Patients |
| March 24 |
Accentia Biopharmaceuticals to Announce Top-Line SinuNase Phase 3
Clinical Trial Results Later Today |
| March 24 |
AVAX to Present Results of Phase I-II Study of MVax at 2008 Meeting
of the American Society of Clinical Oncology (ASCO) |
| March 24 |
Revised: Challenging the Norm May Lead to New Therapy for Type 2
Diabetes |
| March 25 |
Accentia Biopharmaceuticals Announces Results on Primary Endpoint
in Clinical Study of SinuNase Lavage |
| March 25 |
Oxford Biomedica Report Encouraging New Phase II Trial Results with
Trovax in Prostate Cancer |
| March 25 |
Chelsea Therapeutics Reports Significant Efficacy of CH-4051 in
Reduction of Collagen-Induced Arthritis in Animal Model |
| March 25 |
Anacor Pharmaceuticals Announces Positive Results from Phase 2a
Clinical Trial of AN2728 in Psoriasis Patients |
| March 25 |
EPIX Pharmaceuticals to Present Phase 2a Alzheimer's Data at
Keystone Symposia |
| March 25 |
Researchers Report Neublastin Virtually Restores Complete Long-term
Sensory Motor Function in Preclinical Studies |
| March 25 |
Circulation Publishes Data Showing Kynapid (Vernakalant
Hydrochloride) Injection Rapidly Converted Short-Duration Atrial
Fibrillation to Sinus Rhythm |
| March 25 |
ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on
Cognition in Humans |
| March 25 |
Nastech Pharmaceutical Company Inc. to Present RNAi Data |
| March 25 |
Yale and Asuragen Scientists Show That a microRNA Can Reduce Lung
Cancer Growth |
| March 25 |
Strong Trend of Effectiveness Indicated in Lipid Sciences' First in
Man Clinical Trial of HDL Selective Delipidation |
| March 26 |
Cancer Researchers at Manhattan-based St. Vincent's Comprehensive
Cancer Center Discover Genes That Can Determine How Patients
Respond to Pre-Leukemia Drug |
| March 26 |
Nventa Announces Positive Interim Immunological Data From HspE7
Phase 1 Cervical Dysplasia Trial |
| March 26 |
Cerus Announces Major Presence at Upcoming International Society of
Blood Transfusion Conference |
| March 26 |
Levitra Therapy Suitable for Men With High Cholesterol |
| March 26 |
Eric J. Topol, M.D., to Present Late-Breaking Lecture About
Advancements in Genomics of Cardiovascular Disease at ACC's 57th
Annual Scientific Session |
| March 26 |
Cerus Announces Major Presence at Upcoming International Society of
Blood Transfusion Conference |
| March 26 |
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in
Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical
Cancer Research Reports |
| March 26 |
CytRx to Present Stroke Recovery Data at the Sixth International
Workshop on The Molecular Biology of Stress Responses |
| March 26 |
Best Practice Database: Complimentary Excerpt of Scientific
Publications Strategy Study |
| March 26 |
Nature Publishes Study by Santaris Pharma Scientists and
Collaborators: LNA-mediated microRNA Silencing in Non-human
Primates |
| March 27 |
ImmuneRegen BioSciences Releases Study Results Showing Homspera
Stimulates Adult Stem Cell Activity |
| March 27 |
Cystic Fibrosis Foundation Announces Positive Early Results for
Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF |
| March 27 |
Vertex Announces Positive Results for VX-770, an Oral
Investigational Agent That Targets a Defective Protein Responsible
for Cystic Fibrosis |
| March 27 |
Vertex Announces Positive Results for VX-770, an Oral
Investigational Agent That Targets a Defective Protein Responsible
for Cys |
| March 27 |
SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials |
| March 27 |
Stem Cell Research Provides Medical Breakthrough to Repair Heart
Cell Damage Created by a Heart Attack |
| March 27 |
Early Research Suggests Umbilical Cord Blood Cell Therapy May
Reduce Progression of Alzheimer's Disease |
| March 27 |
Orexo Announces Results Confirming the Clinical Profile of OX17 In
Reflux Disease (GERD) |
| March 27 |
Kaiser Permanente Study Shows That a Larger Abdomen in Midlife
Increases Risk of Dementia |
| March 27 |
New data presented at European Association of Urology (EAU)
Congress in Milan |
| March 27 |
Genfit Shows Encouraging Results in GFT505 First Clinical Trial of
Efficacy |
| March 27 |
IntelliPharmaCeutics Announces Successful Completion of a Pilot
Clinical Trial for its Abuse and Alcohol Resistant Sustained
Release Oxycodone |
| March 27 |
RxGen and Santaris Pharma Use LNA-antimiR Technology to antagonize
the liver-expressed microRNA-122 in Non-Human Primates and to
Safely Lower Serum Cholesterol |
| March 28 |
Evotec's EVT 101 Shown to Penetrate the Brain in Man and to
Modulate Brain Activity during the Performance of Cognitive Tasks |
| March 28 |
Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4
Trial |
| March 28 |
Genaera Corporation Announces MSI-1436 Data Presented at Society of
Neuroscience Meeting |
| March 28 |
LDL Particle Measurement by NMR Recognized in Consensus Statement
by the American Diabetes Association and the American College of
Cardiology |
| March 28 |
Sirtris Pharmaceuticals Scientific Advisor Shows SIRT1 Activation
Improves Huntington's Disease In Preclinical Model |
| March 28 |
Positive Results from Visudyne Combination Therapy Study Reported
at Annual Macula Society Conference |
| March 28 |
VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine
Symposia |
| March 31 |
UCB (BE) - Phase II results for CDP791 in non-small cell lung
cancer support further clinical development |
| March 31 |
Angiomax Demonstrated Improved Outcomes in Acute Heart Attack
Patients Undergoing Primary Angioplasty Independent of Individual
Risk Factors |
| March 31 |
Crestor Outcomes Study Jupiter Closes Early Due To Unequivocal
Evidence Of Benefit |
| March 31 |
Update on Achieve: A Study of Merck's Investigational
Extended-Release Niacin/Laropiprant (Cordaptive) |
| March 31 |
12-Month Data From Endeavor IV Show Strong Clinical Efficacy of
Medtronic's Drug-Eluting Stent Across All Patient Groups |
| March 31 |
Merck/Schering-Plough Pharmaceuticals Comments on Results of the
Enhance Study |
| March 31 |
ANX-201 Demonstrates a Unique Resistance Profile in Preclinical
Tests |
| March 31 |
Vertex Pharmaceuticals Announces Acceptance of Late-Breaker
Abstract on Telaprevir |
| March 31 |
Synvista Therapeutics Presents New Preclinical Data Demonstrating
the Value of Haptoglobin Genotype Testing In Diabetes at ACC
Scientific Sessions |
| March 31 |
BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack |
| March 31 |
Phase III Data Showed Taranabant, Merck's Investigational Medicine
to Treat Obesity, Led to Statistically Significant Weight Loss |
| March 31 |
Abbott's XIENCE V Drug Eluting Stent Demonstrates Consistent and
Positive Clinical Outcomes Out to Two Years |
| March 31 |
Alnylam Presents Pre-clinical Data from Hypercholesterolemia, Liver
Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy (PML)
Programs at RNAi Keystone Symposium |
| March 31 |
Drug-Eluting Stents Outperform Bare Stents in Heart Attack |
| March 31 |
Gamma Secretase Modulators Show Promise in Alzheimer's Disease
Animal Model Efficacy Studies, According to Research Conducted by
TorreyPines Therapeutics |
| March 31 |
Endeavor Stent Safety Profile Affirmed in Long-Term Experience |
| March 31 |
Delcath Systems Presents Positive Phase II Data on Delcath PHP
System in Treatment of Inoperable Liver Metastases |
| March 31 |
Large Study Gives Nod to Drug-Eluting Stents in Heart Attack |
| March 31 |
MIV Preliminary Nine-Month Human Data Affirms Excellent Safety and
Efficacy of VESTAsync Polymer-Free Drug-Eluting Stent |
| March 31 |
Novelos Therapeutics Announces Continued Encouraging Results in
Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Harvard Cancer
Center |
| March 31 |
Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in
Study of Patients With Genetic Sodium Channel Disorder |
| March 31 |
Spirit II Results Support Strength of Boston Scientific's Two
Drug-Eluting Stent Platforms |
| March 31 |
Seven Abstracts Featuring Exelixis Compounds Accepted for
Presentation at 2008 ASCO Annual Meeting |
| March 31 |
SPIRIT II Explores Long-Term Performance of XIENCE V Stent |
| March 31 |
Abbott's Phase III Studies of Investigational TriLipix (ABT-335),
in Combination With Statins, Meets Primary Endpoints on Improving
LDL, Triglycerides and HDL |
| March 31 |
Argos Therapeutics Presents Positive Phase 1 Safety Data for its
Arcelis Platform in HIV at Keystone Symposia |
| March 31 |
Landmark OnTarget Trial Demonstrates Micardis is Equally Effective
as Ramipril, with Fewer Discontinuations, in a Broad High-Risk
Cardiovascular Population |
| March 31 |
King Pharmaceuticals Presents Positive Results of CorVue Phase III
Clinical Trials at the American College of Cardiology (ACC) Annual
Scientific Conference |
| March 31 |
Patients Treated with Merck's Investigational Extended-Release
Niacin/Laropiprant (Cordaptive) Reported Significantly Less
Flushing Than Patients Treated with Niaspan in Phase III Study |
| March 31 |
New Data Showed Actos (pioglitazone HCl) Prevented Progression of
Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes |
| March 31 |
Lotrel, a Single-Pill Combination for Treating High Blood Pressure,
Reduced Cardiovascular Events by 20% in High-Risk Patients |
| March 31 |
Repros Reports Interim Safety Results From Ongoing One-Year Open
Label Study of Proellex(R) in the Treatment of Uterine Fibroids |
